Bioventix plc
(“Bioventix” or “the Company”)
Siemens Launches
New Troponin Test
The Board has become aware of the launch of a new test by
Siemens for troponin, a key biomarker used in heart attack
diagnostics. This launch is significant for Bioventix as the
test uses antibodies created by Bioventix and accordingly the
Company will receive product royalties based on Siemens activities
in this area. There is more detailed information on the
Siemens web-site:
http://www.siemens.com/press/en/pressrelease/?press=/en/pressrelease/2017/healthineers/pr2017040269hcen.htm&content[]=HC
For further information please
contact:
Bioventix
plc
Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
|
|
|
finnCap Ltd
Geoff Nash/Simon Hicks
Stephen Norcross |
Corporate Finance
Corporate Broking |
Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and
commercial supply of high-affinity monoclonal antibodies with a
primary focus on their application in clinical diagnostics, such as
in automated immunoassays used in blood testing. The antibodies
created at Bioventix are generated in sheep and are of particular
benefit where the target is present at low concentration and where
conventional monoclonal or polyclonal antibodies have failed to
produce a suitable reagent. Bioventix currently offers a portfolio
of antibodies to customers for both commercial use and R&D
purposes, for the diagnosis or monitoring of a broad range of
conditions, including heart disease, cancer, fertility, thyroid
function and drug abuse. Bioventix currently supplies antibody
products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its
shares are traded on AIM under the symbol BVXP.
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.